



## Efficacy, Safety, and Immunogenicity of Hepatitis B Vaccines

Guest Editor:

### Dr. Benjamin J. Burwitz

Vaccine & Gene Therapy Institute,  
Oregon National Primate  
Research Center, Oregon Health  
& Science University, Beaverton,  
OR, USA

Deadline for manuscript  
submissions:

**closed (31 December 2023)**

### Message from the Guest Editor

Dear Colleagues,

There are currently 296 million people living with chronic hepatitis B (HepB) worldwide, and nearly 1 million of these individuals will die each year from disease-related complications. There are multiple hepatitis B vaccines approved for use by international health regulatory agencies, yet the prevalence of HepB continues to rise. This is due, in part, to HepB vaccine non-responsiveness in 5–10% of patients. This issue focuses on efforts to safely improve the efficacy of HepB vaccines by expanding our understanding of non-responsiveness, testing new adjuvants and vectors, and enhancing vaccine stability during transport, with the goal of making the HepB vaccine available and protective to larger numbers of individuals globally.

Dr. Benjamin J. Burwitz  
*Guest Editor*





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Ralph A. Tripp

Department of Infectious  
Diseases, College of Veterinary  
Medicine, University of Georgia,  
Athens, GA 30602-7387, USA

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.**

**Journal Rank:** JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

## Contact Us

---

*Vaccines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)